Vidaza Related Clinical Trials
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Terminated]
Ph II Study of Azacitidine in Myelofibrosis [Active, not recruiting]
Vidaza to Restore Hormone Thx Prostate [Active, not recruiting]
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia [Recruiting]
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer [Recruiting]
Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome (MDS) Who Are Candidates For Allogeneic Hematopoietic Cell Transplant [Recruiting]
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes [Recruiting]
Azacitidine and Lenalidomide for Acute Myeloid Leukemia [Recruiting]
Ph I Study of PXD101 and 5-Aza in Advanced Hematologic Malignancies [Recruiting]
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer [Recruiting]
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies [Recruiting]
Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes [Not yet recruiting]
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) [Not yet recruiting]
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine [Recruiting]
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) [Recruiting]
Azacitidine and CAPOX in Metastatic Colorectal Cancer [Recruiting]
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma [Recruiting]
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function [Recruiting]
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy [Recruiting]
A Study of 5-Azacitidine (VidazaŽ) in Patients With Chronic Myelomonocytic Leukemia [Recruiting]
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) [Recruiting]
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer [Recruiting]
Azacitidine and MS-275 in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer [Recruiting]
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia [Recruiting]
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) [Recruiting]
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients Previously Treated With Docetaxel [Recruiting]
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia [Recruiting]
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) [Recruiting]
5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy [Recruiting]
Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes [Recruiting]
Randomized Allogeneic Azacitidine Study [Recruiting]
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia [Active, not recruiting]
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care [Completed]
Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia [Recruiting]
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed AML or MDS [Recruiting]
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma [Active, not recruiting]
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes [Recruiting]
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia [Completed]
MGCD0103 Administered in Combination With Azacitidine (VidazaŽ) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma [Recruiting]
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) [Recruiting]
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer [Recruiting]
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS [Recruiting]
AVIDA The VidazaŽ (Azacitidine) Patient Registry [Recruiting]
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Recruiting]
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment [Completed]
Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome) [Not yet recruiting]
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia [Recruiting]
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes [Active, not recruiting]
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Recruiting]
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome [Completed]
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS [Active, not recruiting]
Combination of 5-Azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes [Recruiting]
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation [Recruiting]
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma [Recruiting]
Azacytidine With Valproic Acid Versus Ara-C in AML/MDS Patients [Active, not recruiting]
Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Treating Patients With Relapsed, Refractory, or Transformed Follicular Lymphoma [Recruiting]
Azacytidine and Valproic Acid in Patients With Advanced Cancers [Active, not recruiting]
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes [Active, not recruiting]
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Recruiting]
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome [Recruiting]
Azacitidine in Treating Patients With Myelofibrosis [Active, not recruiting]
A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) [Recruiting]
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome [Completed]
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Active, not recruiting]
5-Azacytidine Valproic Acid and ATRA in AML and High Risk MDS [Recruiting]
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma [Recruiting]
Revlimid and Azacitidine for Treating Advanced Myelodysplastic Syndrome (MDS) [Recruiting]
A Phase II Study of Maintenance With Azacitidine in MDS Patients [Recruiting]
Azacitidine as Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia in Complete Remission After Chemotherapy [Recruiting]
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma [Recruiting]
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Prostate Cancer [Completed]
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes [Recruiting]
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy [Recruiting]
Azacitidine and Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery [Recruiting]
Phase I/II 5-Azacytidine Plus VPA Plus ATRA [Active, not recruiting]
PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases [Recruiting]
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk MDS or Acute Myelogenous Leukemia
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide [Recruiting]
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome [Recruiting]
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes [Recruiting]
Azacitidine, Darbepoetin Alfa, and G-CSF in Treating Patients With Myelodysplastic Syndromes [Recruiting]
Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx) [Recruiting]
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major [Terminated]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Decitabine Versus Supportive Care in Adults With Advanced-Stage MDS [Completed]
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure [Recruiting]
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes [Terminated]
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-Azacitidine (VidazaŽ) [Recruiting]
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) [Recruiting]
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Recruiting]
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma [Recruiting]
Decitabine in Treating Patients With Myelodysplastic Syndrome [No longer recruiting]
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer [Completed]
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) [Recruiting]
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas [Recruiting]
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders [Suspended]
Decitabine in Treating Patients With Advanced Solid Tumors [No longer recruiting]
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Completed]
|
